Final CFP MultiCardioNER (CLEF/BioASQ 2024): Clinical Named Entity Recognition adaptation shared task (multilingual & cardiology)
Martin Krallinger via Corpora <[email protected]> Fri, 10 May 2024 10:59:47 +0200
| Newsgroups | gmane.science.linguistics.corpora,gmane.org.w3c.semantic-web |
|---|---|
| Message-ID | <CAMx+MKEOtaJ+iNAmhC1KV2z8X6WRZE_9OWCCTdj5Zbdg_voNVg@mail.gmail.com> |
--===============5790612878206764740== Content-Type: multipart/alternative; boundary="000000000000a0c557061815c276" --000000000000a0c557061815c276 Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: quoted-printable (Apologies for cross-posting) *Final CFP MultiCardioNER (CLEF/BioASQ 2024): Clinical Named Entity Recognition adaptation shared task (multilingual & cardiology)* *https://temu.bsc.es/multicardioner/ <https://temu.bsc.es/multicardioner/>* The MultiCardioNER track focuses on the adaptation of clinical NER systems to specific high impact clinical application domains (cardiovascular diseases, the leading cause of death globally) as well as to multiple languages (*English, Spanish and Italian*), focusing on two clinical entity types: diseases and medications. *Key information:* =C2=B7 *Web*: https://temu.bsc.es/multicardioner =C2=B7 *Data*: https://zenodo.org/records/11103522 =C2=B7 *BioASQ** web*: http://bioasq.org/ =C2=B7 *Registration**:* https://temu.bsc.es/multicardioner/registrat= ion/ *Motivation*The extraction of clinical variables from medical content is key to enable efficient healthcare data analytics. Due to the highly specialized medical language, with considerable variation depending on the medical discipline, more specialized automatic semantic annotation resources are needed, not only for English but also other languages. This is particularly true for clinical content related to cardiovascular diseases (CVDs), which represent the leading cause of death globally, responsible for approximately 17.9 million deaths/year. The MultiCardioNER task will focus on the automatic recognition of two key clinical variables or concept types, namely diseases and medications in cardiology clinical case documents with the following two aims: =C2=B7 Adaptation of general clinical concept recognition systems to cardiology case reports to assess and determine how well such systems can be adapted to high impact clinical application domains / specialties (cardiology disease NER - CardioDis subtrack: Spanish). =C2=B7 Promote the comparative assessment and development of clinical entity recognition systems for multiple languages (i.e., medication mention detection) as well as adaptation to specific medical specialties (MultiDrug subtrack: English, Spanish and Italian) To enable the adaptation of general medical NER systems for diseases and medications the MultiCardioNER task will rely on a training collection of 1000 general clinical case reports in Spanish annotated with diseases (Spanish) and medications (English, Spanish and Italian). Moreover, to be able to adapt such general medical NER approaches to cardiology case reports a development set of 250 cardiology cases will be released. The test set will consist of an additional test collection of 250 cardiology case reports. The evaluation of systems for this task will use flat evaluation, mainly micro-averaged Precision, Recall and F-measure (MiF). Sub-tracks: *Subtask 1 (CardioDis): *Spanish adaptation of disease recognition systems to the cardiology domain *Subtask 2 (MultiDrug): *Multilingual (Spanish, English and Italian) adaptation of medication recognition systems to the cardiology domain *Tentative schedule* =C2=B7 MultiCardioNER Train+Dev Set Release April 9th, 2024 =C2=B7 MultiCardioNER Annotation Guidelines Release April = 17th, 2024 =C2=B7 MultiCardioNER Gazetteer Release April 17th, 2024 =C2=B7 MultiCardioNER Test Set Texts Release May 2nd, 2024 =C2=B7 Participant Test Predictions Deadline May 15th, 2024 =C2=B7 Participant Evaluation Result Release May 19th, = 2024 =C2=B7 Submission of Participant Papers Deadline May 31st, 2024 =C2=B7 Notification of Acceptance of Participant Papers Jun= e 24th, 2024 =C2=B7 Submission of Camera-ready Participant Papers Deadline July 8th, 2024 =C2=B7 BioASQ @ CLEF2024 September 9th-12th, 2024 *Publications & conference* Following previous BioASQ/CLEF efforts, participating teams will be invited to contribute a short systems description paper for the CLEF 2024 proceedin= gs, and to give a short presentation of their approach at the BioASQ workshop at the CLEF 2024 conference (September 09-12, 2024, in Grenoble, France) *The **MultiCardioNER Organizers & collaborators:* - Salvador Lima-L=C3=B3pez, Barcelona Supercomputing Center (BSC), Spain - Eul=C3=A0lia Farr=C3=A9-Maduell, Barcelona Supercomputing Center (BSC)= , Spain - Jan Rodr=C3=ADguez-Miret, Barcelona Supercomputing Center (BSC), Spain - Martin Krallinger, Barcelona Supercomputing Center (BSC), Spain - Anastasios Nentidis, National Center for Scientific Research Demokritos, Greece - Anastasia Krithara, National Center for Scientific Research Demokritos, Greece - Georgios Katsimpras, National Center for Scientific Research Demokritos, Greece - Livia Lilli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy - Jacopo Lenkowicz, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy - Jonathan Kossoff, University College London Hospitals NHS Foundation Trust, UK - Giovanna Ceroni, University College London, UK - Anoop Shah, University College London Hospitals NHS Foundation Trust, UK =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D Martin Krallinger, Dr. Head of NLP for Biomedical Information Analysis Unit Barcelona Supercomputing Center (BSC-CNS) https://www.linkedin.com/in/martin-krallinger-85495920/ =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D --000000000000a0c557061815c276 Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: quoted-printable <div dir=3D"ltr"><div dir=3D"ltr"><p class=3D"MsoNormal" style=3D"margin:0c= m;font-size:12pt;font-family:Calibri,sans-serif"><span lang=3D"ES" style=3D= "font-size:11pt;font-family:Arial,sans-serif;color:black">(</span><span sty= le=3D"font-size:11pt;font-family:Arial,sans-serif;color:black">Apologies fo= r cross-posting)</span><span style=3D"font-family:Arial,sans-serif"></span>= </p><p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:C= alibri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</spa= n></p><p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family= :Calibri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</s= pan></p><p class=3D"MsoNormal" align=3D"center" style=3D"margin:0cm;text-al= ign:center;font-size:12pt;font-family:Calibri,sans-serif"><b><span style=3D= "font-size:10pt;color:black"><span class=3D"gmail-il">Final CFP</span>=C2= =A0<span class=3D"gmail-il">MultiCardioNER</span>=C2=A0(CLEF/BioASQ 2024): = Clinical Named Entity Recognition adaptation shared task (multilingual &= ; cardiology)</span></b></p><p class=3D"MsoNormal" style=3D"margin:0cm;font= -size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-family:Arial= ,sans-serif">=C2=A0</span></p><p class=3D"MsoNormal" align=3D"center" style= =3D"margin:0cm;text-align:center;font-size:12pt;font-family:Calibri,sans-se= rif"><u><span style=3D"font-size:10pt;color:rgb(17,85,204)"><a href=3D"http= s://temu.bsc.es/multicardioner/" target=3D"_blank" style=3D"color:blue">htt= ps://temu.bsc.es/<span class=3D"gmail-il">multicardioner</span>/</a></span>= </u><span style=3D"font-family:Arial,sans-serif"></span></p><p class=3D"Mso= Normal" align=3D"center" style=3D"margin:0cm;text-align:center;font-size:12= pt;font-family:Calibri,sans-serif"><span style=3D"font-size:11pt;font-famil= y:Arial,sans-serif;color:black">=C2=A0</span><span style=3D"font-family:Ari= al,sans-serif"></span></p><p class=3D"MsoNormal" style=3D"margin:0cm;text-a= lign:justify;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"= font-size:10pt;color:black">The=C2=A0</span><span lang=3D"EN-US" style=3D"f= ont-size:10pt;color:black"><span class=3D"gmail-il">MultiCardioNER</span></= span><span style=3D"font-size:10pt;color:black">=C2=A0track focuses on the<= /span><span style=3D"font-size:10pt;color:black">=C2=A0<span lang=3D"EN-US"= >adaptation of clinical=C2=A0<span class=3D"gmail-il">NER</span>=C2=A0syste= ms to specific high impact clinical application domains (</span></span><spa= n style=3D"font-size:10pt;color:black">cardiovascular diseases</span><span = lang=3D"EN-US" style=3D"font-size:10pt;color:black">,</span><span lang=3D"E= N-US" style=3D"font-size:10pt;color:black">=C2=A0</span><span style=3D"font= -size:10pt;color:black">the leading cause of death globally</span><span lan= g=3D"EN-US" style=3D"font-size:10pt;color:black">) as well as to multiple l= anguages (<b>English, Spanish and Italian</b>), focusing on two clinical en= tity types: diseases and medications.</span><span style=3D"font-size:10pt;c= olor:black"></span></p><p class=3D"MsoNormal" style=3D"margin:0cm;text-alig= n:justify;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"fon= t-family:Arial,sans-serif">=C2=A0</span></p><p class=3D"MsoNormal" style=3D= "margin:0cm;font-size:12pt;font-family:Calibri,sans-serif"><b><span style= =3D"font-size:10pt;color:black">Key information:</span></b><span style=3D"f= ont-family:Arial,sans-serif"></span></p><p class=3D"MsoNormal" style=3D"mar= gin:0cm 0cm 0cm 51.8pt;vertical-align:baseline;font-size:12pt;font-family:C= alibri,sans-serif"><span style=3D"font-size:10pt;font-family:Symbol;color:b= lack">=C2=B7<span style=3D"font-variant-numeric:normal;font-variant-east-as= ian:normal;font-variant-alternates:normal;font-kerning:auto;font-feature-se= ttings:normal;font-stretch:normal;font-size:7pt;line-height:normal;font-fam= ily:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0= </span></span><b><span style=3D"font-size:10pt;color:black">Web</span></b><= span style=3D"font-size:10pt;color:black">:=C2=A0<a href=3D"https://temu.bs= c.es/multicardioner" target=3D"_blank">https://temu.bsc.es/<span class=3D"g= mail-il">multicardioner</span></a></span><span style=3D"font-size:10pt;font= -family:Arial,sans-serif;color:black"></span></p><p class=3D"MsoNormal" sty= le=3D"margin:0cm 0cm 0cm 51.8pt;vertical-align:baseline;font-size:12pt;font= -family:Calibri,sans-serif"><span style=3D"font-size:10pt;font-family:Symbo= l;color:black">=C2=B7<span style=3D"font-variant-numeric:normal;font-varian= t-east-asian:normal;font-variant-alternates:normal;font-kerning:auto;font-f= eature-settings:normal;font-stretch:normal;font-size:7pt;line-height:normal= ;font-family:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2= =A0=C2=A0</span></span><b><span style=3D"font-size:10pt;color:black">Data</= span></b><span style=3D"font-size:10pt;color:black">:</span>=C2=A0<span sty= le=3D"font-size:10pt;font-family:Arial,sans-serif;color:black"></span><span= style=3D"font-family:Arial,Helvetica,sans-serif;font-size:small"><a href= =3D"https://zenodo.org/records/11103522">https://zenodo.org/records/1110352= 2</a></span></p><p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 51.8pt;v= ertical-align:baseline;font-size:12pt;font-family:Calibri,sans-serif"><span= style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<span style= =3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-variant= -alternates:normal;font-kerning:auto;font-feature-settings:normal;font-stre= tch:normal;font-size:7pt;line-height:normal;font-family:"Times New Rom= an"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><b><span = lang=3D"EN-US" style=3D"font-size:10pt;color:black">BioASQ</span></b><b><sp= an style=3D"font-size:10pt;color:black">=C2=A0web</span></b><span style=3D"= font-size:10pt;color:black">:=C2=A0<a href=3D"http://bioasq.org/" target=3D= "_blank">http://bioasq.org/</a></span></p><p class=3D"MsoNormal" style=3D"m= argin:0cm 0cm 0cm 51.8pt;vertical-align:baseline;font-size:12pt;font-family= :Calibri,sans-serif"><span style=3D"font-size:10pt;font-family:Symbol;color= :black">=C2=B7<span style=3D"font-variant-numeric:normal;font-variant-east-= asian:normal;font-variant-alternates:normal;font-kerning:auto;font-feature-= settings:normal;font-stretch:normal;font-size:7pt;line-height:normal;font-f= amily:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2= =A0</span></span><b><span style=3D"font-size:10pt;color:black">Registration= </span></b><b><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">:</= span></b><b><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">=C2= =A0</span></b><span style=3D"font-size:10pt;color:black"><a href=3D"https:/= /temu.bsc.es/multicardioner/registration/" target=3D"_blank">https://temu.b= sc.es/<span class=3D"gmail-il">multicardioner</span>/registration/</a></spa= n></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justif= y;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:1= 0pt;color:rgb(17,85,204)"><br></span><b><span style=3D"font-size:10pt;color= :black">Motivation<br></span></b><span style=3D"font-size:10pt;color:black"= >The extraction of clinical variables from medical content is key to enable= efficient healthcare data analytics. Due to the highly specialized medical= language, with considerable variation depending on the medical=C2=A0</span= ><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">discipline</span= ><span style=3D"font-size:10pt;color:black">, more specialized automatic se= mantic annotation resources are needed, not only for English but also other= languages.</span></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;t= ext-align:justify;font-size:12pt;font-family:Calibri,sans-serif"><span styl= e=3D"font-size:10pt;color:black">This is particularly true for clinical con= tent related to cardiovascular diseases (CVDs), which represent the leading= cause of death globally, responsible for approximately 17.9 million deaths= /year.</span></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-a= lign:justify;font-size:12pt;font-family:Calibri,sans-serif"><span lang=3D"E= N-US" style=3D"font-size:10pt;color:black">The</span><span lang=3D"EN-US" s= tyle=3D"font-size:10pt;color:black">=C2=A0</span><span style=3D"font-size:1= 0pt;color:black"><span class=3D"gmail-il">MultiCardioNER</span>=C2=A0</span= ><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">task=C2=A0</span= ><span style=3D"font-size:10pt;color:black">will focus on the automatic rec= ognition of two key clinical variables or concept types, namely diseases an= d medications</span><span style=3D"font-size:10pt;color:black">=C2=A0</span= ><span style=3D"font-size:10pt;color:black">in cardiology clinical case doc= uments with the following two aims:</span></p><p style=3D"margin:10pt 0cm 0= cm 36pt;text-align:justify;font-size:12pt;font-family:Calibri,sans-serif"><= span style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<span st= yle=3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-vari= ant-alternates:normal;font-kerning:auto;font-feature-settings:normal;font-s= tretch:normal;font-size:7pt;line-height:normal;font-family:"Times New = Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span = style=3D"font-size:10pt;color:black">Adaptation of general clinical concept= recognition systems to cardiology case reports to assess and determine how= well such systems can be adapted to high impact clinical application domai= ns / specialties (cardiology disease=C2=A0<span class=3D"gmail-il">NER</spa= n>=C2=A0- CardioDis subtrack: Spanish).</span></p><p style=3D"margin:10pt 0= cm 0cm 36pt;text-align:justify;font-size:12pt;font-family:Calibri,sans-seri= f"><span style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<spa= n style=3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-= variant-alternates:normal;font-kerning:auto;font-feature-settings:normal;fo= nt-stretch:normal;font-size:7pt;line-height:normal;font-family:"Times = New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><s= pan style=3D"font-size:10pt;color:black">Promote the comparative assessment= and development of clinical entity recognition systems for multiple langua= ges (i.e., medication mention detection) as well as adaptation to specific = medical specialties (MultiDrug subtrack: English, Spanish and Italian)</spa= n></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:justif= y;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:1= 0pt;color:black">To enable the adaptation of general medical=C2=A0<span cla= ss=3D"gmail-il">NER</span>=C2=A0systems for diseases and medications the=C2= =A0<span class=3D"gmail-il">MultiCardioNER</span>=C2=A0task will rely on a = training collection of 1000 general clinical case reports in Spanish annota= ted with diseases (Spanish) and medications (English, Spanish and Italian).= </span></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:j= ustify;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s= ize:10pt;color:black">Moreover,=C2=A0</span><span lang=3D"EN-US" style=3D"f= ont-size:10pt;color:black">t</span><span style=3D"font-size:10pt;color:blac= k">o be able to adapt such general medical=C2=A0<span class=3D"gmail-il">NE= R</span>=C2=A0approaches to cardiology case reports a development set of 25= 0 cardiology cases will be released.</span><span style=3D"font-size:10pt;co= lor:black">=C2=A0</span><span style=3D"font-size:10pt;color:black">The test= set will consist of an additional test collection of 250 cardiology case r= eports</span><span lang=3D"EN-US" style=3D"font-size:10pt;color:black">.</s= pan></p><p class=3D"MsoNormal" style=3D"margin:10pt 0cm 0cm;text-align:just= ify;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size= :10pt;color:black">The evaluation of systems for this task will use flat ev= aluation, mainly micro-averaged Precision, Recall and F-measure (MiF).</spa= n></p><p class=3D"MsoNormal" style=3D"margin:0cm 0cm 12pt;font-size:12pt;fo= nt-family:Calibri,sans-serif"><span style=3D"font-family:Arial,sans-serif">= =C2=A0</span></p><p class=3D"MsoNormal" style=3D"margin:0cm 0cm 12pt;font-s= ize:12pt;font-family:Calibri,sans-serif"><span lang=3D"ES" style=3D"font-fa= mily:Arial,sans-serif">S</span><span style=3D"font-size:10pt;color:black">u= b-tracks:</span><span style=3D"font-family:Arial,sans-serif"></span></p><p = class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font-fa= mily:Calibri,sans-serif"><b><span style=3D"font-size:10pt;color:black">Subt= ask 1 (CardioDis):=C2=A0</span></b><span style=3D"font-size:10pt;color:blac= k">Spanish adaptation of disease recognition systems to the cardiology doma= in<b></b></span></p><p class=3D"MsoNormal" style=3D"margin:0cm 0cm 0cm 36pt= ;font-size:12pt;font-family:Calibri,sans-serif"><b><span style=3D"font-size= :10pt;color:black">=C2=A0</span></b></p><p class=3D"MsoNormal" style=3D"mar= gin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif"><b><spa= n style=3D"font-size:10pt;color:black">Subtask 2 (MultiDrug):=C2=A0</span><= /b><span style=3D"font-size:10pt;color:black">Multilingual (Spanish, Englis= h and Italian) adaptation of medication recognition systems to the cardiolo= gy domain<br><b><br></b></span></p><p class=3D"MsoNormal" style=3D"margin:0= cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif"><span style= =3D"font-size:10pt;color:black"><b><br></b></span></p><p class=3D"MsoNormal= " style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-= serif"><span style=3D"font-size:10pt;color:black"><b>Tentative schedule</b>= </span><span style=3D"font-family:Arial,sans-serif"></span></p><p style=3D"= margin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif"><spa= n style=3D"font-size:10pt;font-family:Symbol;color:black">=C2=B7<span style= =3D"font-variant-numeric:normal;font-variant-east-asian:normal;font-variant= -alternates:normal;font-kerning:auto;font-feature-settings:normal;font-stre= tch:normal;font-size:7pt;line-height:normal;font-family:"Times New Rom= an"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span sty= le=3D"font-size:10pt;color:black"><span class=3D"gmail-il">MultiCardioNER</= span>=C2=A0Train+Dev Set Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0= =C2=A0=C2=A0=C2=A0 April 9th, 2024</span></p><p style=3D"margin:0cm 0cm 0cm= 36pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-si= ze:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-n= umeric:normal;font-variant-east-asian:normal;font-variant-alternates:normal= ;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-si= ze:7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0= =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:= 10pt;color:black"><span class=3D"gmail-il">MultiCardioNER</span>=C2=A0Annot= ation Guidelines Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2= =A0=C2=A0=C2=A0 April 17th, 2024</span></p><p style=3D"margin:0cm 0cm 0cm 3= 6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size= :10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num= eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f= ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size= :7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2= =A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:10p= t;color:black"><span class=3D"gmail-il">MultiCardioNER</span>=C2=A0Gazettee= r Release=C2=A0 April 17th, 2024</span></p><p style=3D"margin:0cm 0cm 0cm 3= 6pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size= :10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-num= eric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;f= ont-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size= :7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2= =A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:10p= t;color:black"><span class=3D"gmail-il">MultiCardioNER</span>=C2=A0Test Set= Texts Release=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0= =C2=A0 May 2nd, 2024</span></p><p style=3D"margin:0cm 0cm 0cm 36pt;font-siz= e:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;font-f= amily:Symbol;color:black">=C2=B7<span style=3D"font-variant-numeric:normal;= font-variant-east-asian:normal;font-variant-alternates:normal;font-kerning:= auto;font-feature-settings:normal;font-stretch:normal;font-size:7pt;line-he= ight:normal;font-family:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2= =A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:10pt;color:blac= k">Participant Test Predictions Deadline=C2=A0=C2=A0</span><span style=3D"c= olor:black;font-size:10pt">May 15th, 2024</span></p><p style=3D"margin:0cm = 0cm 0cm 36pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"= font-size:10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-va= riant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates= :normal;font-kerning:auto;font-feature-settings:normal;font-stretch:normal;= font-size:7pt;line-height:normal;font-family:"Times New Roman"">= =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font= -size:10pt;color:black">Participant Evaluation Result Release=C2=A0=C2=A0= =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 Ma= y 19th, 2024</span></p><p style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;f= ont-family:Calibri,sans-serif"><span style=3D"font-size:10pt;font-family:Sy= mbol;color:black">=C2=B7<span style=3D"font-variant-numeric:normal;font-var= iant-east-asian:normal;font-variant-alternates:normal;font-kerning:auto;fon= t-feature-settings:normal;font-stretch:normal;font-size:7pt;line-height:nor= mal;font-family:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0= =C2=A0=C2=A0</span></span><span style=3D"font-size:10pt;color:black">Submis= sion of Participant Papers Deadline=C2=A0=C2=A0=C2=A0=C2=A0 May 31st, 2024<= /span></p><p style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Ca= libri,sans-serif"><span style=3D"font-size:10pt;font-family:Symbol;color:bl= ack">=C2=B7<span style=3D"font-variant-numeric:normal;font-variant-east-asi= an:normal;font-variant-alternates:normal;font-kerning:auto;font-feature-set= tings:normal;font-stretch:normal;font-size:7pt;line-height:normal;font-fami= ly:"Times New Roman"">=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0<= /span></span><span style=3D"font-size:10pt;color:black">Notification of Acc= eptance of Participant Papers=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2= =A0=C2=A0=C2=A0 June 24th, 2024</span></p><p style=3D"margin:0cm 0cm 0cm 36= pt;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:= 10pt;font-family:Symbol;color:black">=C2=B7<span style=3D"font-variant-nume= ric:normal;font-variant-east-asian:normal;font-variant-alternates:normal;fo= nt-kerning:auto;font-feature-settings:normal;font-stretch:normal;font-size:= 7pt;line-height:normal;font-family:"Times New Roman"">=C2=A0=C2= =A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:10p= t;color:black">Submission of Camera-ready Participant Papers Deadline=C2=A0= =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 July 8th, 2024</span= ></p><p style=3D"margin:0cm 0cm 0cm 36pt;font-size:12pt;font-family:Calibri= ,sans-serif"><span style=3D"font-family:Symbol">=C2=B7<span style=3D"font-v= ariant-numeric:normal;font-variant-east-asian:normal;font-variant-alternate= s:normal;font-kerning:auto;font-feature-settings:normal;font-stretch:normal= ;font-size:7pt;line-height:normal;font-family:"Times New Roman"">= =C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0</span></span><span style=3D"font-size:= 10pt;color:black">BioASQ @ CLEF2024=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0=C2= =A0=C2=A0=C2=A0=C2=A0=C2=A0=C2=A0 September 9th-12th, 2024<br><br><br></spa= n><span style=3D"font-family:Arial,sans-serif"></span></p><p style=3D"margi= n:0cm;background-image:initial;background-position:initial;background-size:= initial;background-repeat:initial;background-origin:initial;background-clip= :initial;font-size:12pt;font-family:"Times New Roman",serif"><b><= span style=3D"font-size:10pt;font-family:Arial,sans-serif">Publications &am= p; conference</span></b><span style=3D"font-size:10pt;font-family:Arial,san= s-serif"></span></p><p style=3D"margin:0cm;text-align:justify;background-im= age:initial;background-position:initial;background-size:initial;background-= repeat:initial;background-origin:initial;background-clip:initial;font-size:= 12pt;font-family:"Times New Roman",serif"><span style=3D"font-var= iant-numeric:normal;font-variant-east-asian:normal;font-variant-alternates:= normal"><span style=3D"font-size:10pt;font-family:Arial,sans-serif">Followi= ng previous BioASQ/CLEF efforts, participating teams will be invited to con= tribute a short systems description paper for the CLEF 202</span><span lang= =3D"EN-US" style=3D"font-size:10pt;font-family:Arial,sans-serif">4</span><s= pan style=3D"font-size:10pt;font-family:Arial,sans-serif">=C2=A0proceedings= , and to give a short presentation of their approach at the BioASQ workshop= at the CLEF 202</span><span lang=3D"EN-US" style=3D"font-size:10pt;font-fa= mily:Arial,sans-serif">4</span><span style=3D"font-size:10pt;font-family:Ar= ial,sans-serif">=C2=A0conference (September 09-12, 2024, in Grenoble</span>= <span lang=3D"EN-US" style=3D"font-size:10pt;font-family:Arial,sans-serif">= ,=C2=A0</span><span style=3D"font-size:10pt;font-family:Arial,sans-serif">F= rance)</span></span></p><p class=3D"MsoNormal" style=3D"margin:0cm;font-siz= e:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:10pt;color:= black"><br></span><span style=3D"font-family:Arial,sans-serif"></span></p><= p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calibr= i,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></p= ><p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Cali= bri,sans-serif"><span style=3D"font-size:10pt;color:black"><br></span><b><s= pan style=3D"font-size:10pt;color:black">The=C2=A0</span></b><b><span lang= =3D"EN-GB" style=3D"font-size:10pt;color:black"><span class=3D"gmail-il">Mu= ltiCardioNER</span>=C2=A0Organizers & collaborators:</span></b><b><span= lang=3D"ES" style=3D"font-size:10pt;color:black"></span></b></p><p class= =3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calibri,sans-= serif"><b><span lang=3D"ES" style=3D"font-size:10pt;color:black">=C2=A0</sp= an></b></p><ul type=3D"disc" style=3D"margin-top:0cm;margin-bottom:0cm"><li= class=3D"MsoNormal" style=3D"margin:0cm;color:black;font-size:12pt;font-fa= mily:Calibri,sans-serif"><span style=3D"font-size:10pt">Salvador Lima-L=C3= =B3pez, Barcelona Supercomputing Center (BSC), Spain</span></li><li class= =3D"MsoNormal" style=3D"margin:0cm;color:black;font-size:12pt;font-family:C= alibri,sans-serif"><span style=3D"font-size:10pt">Eul=C3=A0lia Farr=C3=A9-M= aduell, Barcelona Supercomputing Center (BSC), Spain</span></li><li class= =3D"MsoNormal" style=3D"margin:0cm;color:black;font-size:12pt;font-family:C= alibri,sans-serif"><span style=3D"font-size:10pt">Jan Rodr=C3=ADguez-Miret,= Barcelona Supercomputing Center (BSC), Spain</span></li><li class=3D"MsoNo= rmal" style=3D"margin:0cm;color:black;font-size:12pt;font-family:Calibri,sa= ns-serif"><span style=3D"font-size:10pt">Martin Krallinger, Barcelona Super= computing Center (BSC), Spain</span></li></ul><ul type=3D"disc" style=3D"ma= rgin-top:0cm;margin-bottom:0cm"><li class=3D"MsoNormal" style=3D"margin:0cm= ;color:black;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"= font-size:10pt">Anastasios Nentidis, National Center for Scientific Researc= h Demokritos, Greece</span></li><li class=3D"MsoNormal" style=3D"margin:0cm= ;color:black;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"= font-size:10pt">Anastasia Krithara, National Center for Scientific Research= Demokritos, Greece</span></li><li class=3D"MsoNormal" style=3D"margin:0cm;= color:black;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"f= ont-size:10pt">Georgios Katsimpras, National Center for Scientific Research= Demokritos, Greece</span></li></ul><ul type=3D"disc" style=3D"margin-top:0= cm;margin-bottom:0cm"><li class=3D"MsoNormal" style=3D"margin:0cm;color:bla= ck;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:= 10pt">Livia Lilli, Fondazione Policlinico Universitario Agostino Gemelli IR= CCS, Italy</span></li><li class=3D"MsoNormal" style=3D"margin:0cm;color:bla= ck;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-size:= 10pt">Jacopo Lenkowicz, Fondazione Policlinico Universitario Agostino Gemel= li IRCCS, Italy</span></li><li class=3D"MsoNormal" style=3D"margin:0cm;colo= r:black;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-= size:10pt">Jonathan Kossoff, University College London Hospitals NHS Founda= tion Trust, UK</span></li><li class=3D"MsoNormal" style=3D"margin:0cm;color= :black;font-size:12pt;font-family:Calibri,sans-serif"><span style=3D"font-s= ize:10pt">Giovanna Ceroni, University College London, UK</span></li><li cla= ss=3D"MsoNormal" style=3D"margin:0cm;color:black;font-size:12pt;font-family= :Calibri,sans-serif"><span style=3D"font-size:10pt">Anoop=C2=A0Shah, Univer= sity College London Hospitals NHS Foundation Trust, UK</span></li></ul><p c= lass=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calibri,s= ans-serif"><span style=3D"font-family:Arial,sans-serif"><br><br></span></p>= <p class=3D"MsoNormal" style=3D"margin:0cm;font-size:12pt;font-family:Calib= ri,sans-serif"><span style=3D"font-family:Arial,sans-serif">=C2=A0</span></= p><div>=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D<br>Martin Krallinger, D= r.<br><span style=3D"font-family:arial,helvetica,sans-serif">Head of NLP fo= r Biomedical Information Analysis Unit<br></span><span style=3D"font-family= :arial,helvetica,sans-serif">Barcelona Supercomputing Center (BSC-CNS)</spa= n></div><div><font face=3D"arial, helvetica, sans-serif"><a href=3D"https:/= /www.linkedin.com/in/martin-krallinger-85495920/" target=3D"_blank">https:/= /www.linkedin.com/in/martin-krallinger-85495920/</a><br></font>=C2=A0=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D</div></div></div> --000000000000a0c557061815c276-- --===============5790612878206764740== Content-Type: text/plain; charset="us-ascii" MIME-Version: 1.0 Content-Transfer-Encoding: 7bit Content-Disposition: inline _______________________________________________ Corpora mailing list -- [email protected] https://list.elra.info/mailman3/postorius/lists/corpora.list.elra.info/ To unsubscribe send an email to [email protected] --===============5790612878206764740==--